A group of 13 individuals have become the first people to be licensed to facilitate psilocybin experiences in the United States outside of clinical trials in...
A new collaboration between Emyria and Australia’s specialist trauma service, the PAX Centre, is aiming to develop a scalable MDMA-assisted therapy model for patients with complex...
Optimi Health has entered into a long-term distribution agreement with Mind Medicine Australia to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules.
PharmAla Biotech Holdings has been named the exclusive supplier of both GMP and engineering MDMA to Awakn LS Europe Holdings Limited.
With an increase in psychedelic research and clinical trials, it is becoming increasingly important to train psychedelic therapists.
Awakn Life Sciences has confirmed it has signed its fourth Licensing Partnership agreement in North America with Ken Starr MD Wellness Group, an addiction treatment facility...
LongeVC has invested in psychedelics startup Freedom Biosciences which is pioneering the use of ketamine and other compounds in next-generation treatments.
Awakn Life Sciences has announced that Awakn Clinics Trondheim is now open and that it has initiated a feasibility study of MDMA leveraging Catalent’s proprietary Zydis...
Tadeusz Hawrot, Founder and Executive Director of the Psychedelic Access and Research European Alliance (PAREA), speaks to Psychedelic Health about how the organisation plans to campaign...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Awakn Life Sciences an Innovation Passport for its proprietary ketamine-assisted therapy for the treatment of...
